Francis Igor Macedo MD, FACS, FSSO
@FrancisIgorMac1
Followers
251
Following
760
Media
41
Statuses
237
Proud dad, lucky husband, Chief, Division of Surgical Oncology, @HCA North FL Hospital, @ucfhcaocalasurg, Associate Professor @UCF
Joined March 2019
Is minimally invasive (robot) #Whipple surgery just as safe as open surgery? Today: #DIPLOMA2 RCT in @NEJMEvidence ➡️ https://t.co/amrQ7hTk4O 288 patients, 14 expert centers, 6 countries 🇳🇱🇮🇹🇩🇪🇧🇪🇪🇸🇸🇪): MIS equally safe as open in experienced centers. With faster recovery,
4
38
82
Highly antecipated ⛽️#pump pub! Superior than best data so far for unresectable intrahepatic cholangioca with TOPAZ-1 trial using gem-cis-durva. mOS 22.3 vs 12.8 mo and 3yr OS 31.5 vs 14.6%. Next 🐾 ➡️RCT @BasGrootKoerkam @JCO_ASCO
PUMP-2 published in JCO! HAIP chemo for intrahepatic cholangiocarcinoma #pump #CCA @FlavioRochaMD @ArndtVogel @curecc @timpawlik @DrAngelaLamarca @LorenzaRimassa @SyedAAhmad5 @JCO_ASCO
https://t.co/vG6tVXEoQ8
0
0
2
Robotic Whipple with portal vein resection. Pretty impressed how robot visualization helped reconstruction. 🤖🚀 @IHPBA @SocSurgOnc @AHPBA @socroboticsurg
2
0
9
ESOPEC trial. Neoadjuvant Chemo superior to chemoRT in resectable esophageal adenoCA. WWYD? @ASCO @SocSurgOnc @myESMO #EsophagealCancer🔥☢️🧪🦀🪡
dailynews.ascopubs.org
Perioperative FLOT improved median overall survival by 29 months compared with neoadjuvant CROSS in resectable, locally advanced esophageal or GEJ adenocarcinoma, translating to a 30% reduction in...
0
1
1
Dont miss out @SocSurgOnc Webinar tomorrow on management of malignant bowel obstructions. 🦀🔪 May 1 at 6PM @AlissaGreenbaum
Don't miss part 1️⃣ of this ✌️part series kicking off with a deep dive into various approaches and strategies aimed at elevating patient care and refining decision-making in this complex clinical scenario. Join us tomorrow! https://t.co/RU20xUWsXO
0
0
3
#PDAC is tough disease. Some steps forward but the road is long ahead.. @SocSurgOnc @PanCAN @ucfhcaocalasurg @AnnalsofSurgery
From the @MDAndersonNews multidisciplinary pancreatic cancer team in time for #SSO2024: Trends Over Time in Recurrence Patterns & Survival Outcomes after Neoadjuvant Therapy & Surgery for #PancreaticCancer
https://t.co/J470TjTlfC There has been a steady improvement in median
0
0
6
Great night to wrap up #SSO24 with old friends, mentors and Surg Onc fellows at UM. 🙌🏻 @NbmerchantMD @DrJashDatta @surgonclady @Kelly_LK86 @NGoelMD @UMJMHSurgery
2
1
14
After 1 year of multiple meetings and preparation, first #HAI pump 🦀⛽️was placed in North Florida @HCAFLHealthcare @ucfhcaocalasurg for pts w stage 4 #colonca.Proud to lead this great team!Our program is 🚀💥@InteraOncology #livermets @AHPBA @IHPBA @SocSurgOnc @ColonCancerAwar
1
2
13
Robotic transhiatal esophagectomy. ICUless, chest tube-less, opioid-less on pod2. 18LNs, - margins. Dc’ed 🏠 POD4. Less is MORE. 📉📈 Great 👁️ during mediastinal dissection w 🤖 platform. 🪡🪢🦀 #EsophagealCancer @ucfhcaocalasurg @SocSurgOnc @Medtwitteer @SAGES_Updates @SU2C
0
0
10
"Trivial" IPMNs as potential target of surveillance discontinuation are out now on @AGA_Gastro 🔥 🧐 After 5 years of surveillance their risk comparable to that of the general population depending on 📏 Cyst size 👴 Patient Age But how did we get here? https://t.co/zUaNcwhssR
4
63
187
General Surgery Chief Resident’s Graduation @ucfhcaocalasurg ! What a pleasure to see these brilliant residents become fine surgeons over last 5 years. 🦀🔪🪢@ourmedschool @UCFGNVIM @Medtwitteer
0
1
6
Spending some good time with family. Tour around 🇮🇹! 🍝🍕🌋🤌🏼🍷
0
0
4
Proud to see our chief resident, Alana Hofmann, operating independetly on her last day of #SurgicalOncology 🦀rotation. Cant wait to see amazing things she will do as Transplant Fellow @uofcincy. 🎓🪢🩸 @ucfhcaocalasurg @hpb_so @me4_so
0
1
12
Hepatic artery infusion for unresectable colorectal cancer liver metastases: Palliation and conversion https://t.co/oRkRbrc130 Superb @SurgJournal study from @michael_lidsky @DukeSurgery @DukeSurgRes #SoMe4HBP @AHPBA @EAHPBA @IHPBA @CHPBAsurg @ASCOPost @SSATNews @AmColSurgCancer
0
10
23
Of the responders (50%-8pts)- median RFS was not reached compared with the 8 non- responders who had a median RFS of 13.4 months. 🧬📈📊
0
0
0
Promising findings of phase I trial- group of patients w #PDAC who responded to personalized RNA neoantigen vaccine and adjuvant #FOLFIRINOX and anti-PD1 #immunotherapy.💡at the end of the tunnel.@Nature @IHPBA @AHPBA @PanCAN
nature.com
Nature - A phase I clinical trial of an adjuvant personalized mRNA neoantigen vaccine, autogene cevumeran, in patients with pancreatic ductal carcinoma demonstrates that the vaccine can...
1
2
10
Had a great time, @Kelly_LK86! Thanks for arranging. Welcome to the Club :) 🦞🍝🍷
Enjoying dinner with the fellows that came before me and Dr Franceschi #SSO2023
@gilihalfteck @surgonclady @FrancisIgorMac1 @MdTiesi Heather Stuart
0
0
4